Automating flow cytometry for objective and reproducible cell therapy QC
This poster presents the ACCELLIXTM solution and how it demonstrated performance across 20+ Leukapheresis samples & control materials.
Automating flow cytometry for objective and reproducible cell therapy QC
Poster presented at ISCT 2025
- Filename
- Accellix-2025-ISCT-Cell-Therapy-QC-Poster.pdf
- Size
- 2 MB
- Format
- application/pdf
Summary
- The Accellix Cell Phenotyping Platform automates sample preparation, voltage calibration, spectral unmixing, data acquisition, and data analysis.
- T Cell and TBNK assay cell subsets were clearly and consistently identified by assay-specific autoclassification software across 30 unique leukapheresis samples, 3 lots of CD Chex Plus®, 15 Accellix instruments, and cell concentration levels ranging from 1 to 50 million cells per mL
- Coefficients of variance (CVs) for 5 replicates (5 instruments) across all samples ranged from 0.81% to 7.69%
- Comparing manual and automated analysis results for each cell subset, the coefficients of determination (R2 values) are all at or above 0.9 and slopes range from 0.98 to 1.03, demonstrating excellent concordance and no systematic bias
The Accellix Platform has the potential to improve cell therapy QC efficiency by providing a simple and rapid workflow that minimizes process variability and subjective data analysis.
Want To Discuss Your Needs?
Complete the form below to get in touch with our team. A bioMérieux expert will be in touch using the contact information you provide. By providing your information, you agree to receive additional emails from bioMérieux about cell and gene therapy quality control.
To find out more about the management of your personal data and to exercise your rights, see our privacy policy.